Chhavi Chadha is a Principle Investigator and Assistant Professor, Department of Internal Medicine on the Clinical Scholar Track, University of Minnesota, Minneapolis. Chadha had completed her MBBS, Kasturba Medical College, Mangalore, India; residency and chief residency, Department of Internal Medicine, Loma Linda University Medical Center, Loma Linda, California; and fellowship, Division of Endocrinology, Diabetes and Metabolism, University of Minnesota, Minneapolis. 2013-present: Principle investigator, D2d: Role of vitamin D in preventing progression of prediabetes to type 2 diabetes. Funded by the National Institutes of Health. 2010-present: Principle investigator, EXSCEL: Exenatide Study of Cardiovascular Event Lowering, a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2010-2014: Principle investigator, TECOS trial evaluating cardiovascular outcomes with sitagliptin. 2010-2011: Coinvestigator, AIM HIGH, the Atherthrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides, the role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol.  

In the role of principle investigator for multicenter randomized controlled trials and projects related to diabetes and cardiovascular disease, I am directly responsible for oversight and mentoring of research coordinators, recruitment assistants and senior research project managers at the HealthPartners Riverside Research Clinic. I have led several clinical trials to test new treatment interventions to improve diabetes care, especially glucose control and cardiovascular risks associated with diabetes and, more recently, diabetes prevention. For the year 2016, through our collaborative effort and skillful execution, we have been successful in exceeding our recruitment goal of 300 subjects for the D2d clinical trial. Being an endocrinologist involved in patient care, I have a vested interest in getting involved in large outcome trials that will eventually set the guidelines for how we manage prediabetes, diabetes and the growing epidemic of obesity in the future.